[Use of biotrof-3 in complex treatment of patients with postinfarct cardiosclerosis].
Results are submitted of clinical, instrumental, and laboratory methods of investigation in 50 patients with postinfarction cardiosclerosis before the start of the treatment and four weeks after conventional cardioactive therapy (control group) and the analogous therapy involving the use of a new biologically active home-produced drug preparation biotroph-3 in a complex therapy of patients with postinfarction cardiosclerosis permits shortening time for the general clinical improvement of the patients' state to be achieved due to apparent antiarrhythmic, antiischemic, and hypotensive effects along with reduction of manifestations of heart failure, as evidenced by the analysis of the results obtained.
Sakharchuk
I I
II
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D000601:Amino Acids, Essential / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D057487:Enzyme Therapy; D006801:Humans; D009203:Myocardial Infarction / Q000503:physiopathology*; D010743:Phospholipids / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000601:Amino Acids, Essential; D000975:Antioxidants; D002317:Cardiovascular Agents; D004338:Drug Combinations; D010743:Phospholipids; D014815:Vitamins